Form 4: CYTOKINETICS Director Opts for Equity Over Cash Retainer

Cytokinetics director Robert Arthur Harrington acquired 197 shares of common stock at $63.44 per share on January 15, 2026, as part of an equity compensation plan.

Summary

• Director Robert Arthur Harrington acquired 197 shares of Cytokinetics Inc. common stock.
• The transaction is scheduled for January 15, 2026, at a price of $63.44 per share.
• These shares are fully vested common stock received in lieu of a cash retainer, under an Equity in Lieu of Cash Retainer Option available to Board members.
• Following this transaction, Mr. Harrington will beneficially own 18,739 shares of common stock.
• The acquisition was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned transaction.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, especially in lieu of cash, is generally a positive signal of confidence and alignment of interests. The pre-planned nature via a 10b5-1 plan makes it a routine, albeit positive, event.

Positives

• Director Robert Arthur Harrington will increase his direct ownership in Cytokinetics Inc. by acquiring 197 shares.
• The acquisition of shares in lieu of a cash retainer demonstrates alignment of the director's interests with shareholders.
• The transaction is pre-planned under a Rule 10b5-1(c) plan, suggesting a structured and transparent approach to equity compensation.

Industry Context

Insider transactions, such as directors acquiring shares, are generally viewed by the market as a positive signal, indicating management's confidence in the company's future prospects and aligning their interests with those of shareholders. This specific transaction, where shares are taken in lieu of cash, further reinforces this alignment, a common practice in corporate governance to incentivize long-term value creation.

Related Party Transactions

• Director Robert Arthur Harrington acquired shares from Cytokinetics Inc. as part of his compensation, which is a related party transaction.

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a positive sign of confidence in the company's future performance.
• The use of equity compensation for directors can reduce cash outflow for the company, potentially benefiting overall financial health.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Transaction, Director Stock Acquisition, Equity Compensation, Robert Arthur Harrington, Rule 10b5-1